DDrare: Database of Drug Development for Rare Diseases

4. 原発性側索硬化症
［臨床試験数：6，薬物数：16（DrugBank：8），標的遺伝子数：19，標的パスウェイ数：32］

Searched query = "Primary lateral sclerosis", "PLS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Carbidopa; Carbidopa-levodopa; DEXMEDETOMIDINE; Dalfampridine; Daraprim; Dexdor; Dexmedetomidine; ESKETAMINE; Esketamine; Ketanest; Ketanest-S; Levetiracetam; Levodopa; PYRIMETHAMINE; Pyrimethamine; Stem Cells

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02868567 (ClinicalTrials.gov)	March 2016	17/3/2016	Use of Dalfampridine in Primary Lateral Sclerosis	A Multicenter, 18-week Open Label Safety and Efficacy Trial of Dalfampridine in Primary Lateral Sclerosis	Motor Neuron Disease, Upper	Drug: dalfampridine	Weill Medical College of Cornell University	Hospital for Special Surgery, New York	Recruiting	18 Years	99 Years	All	35	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02868567
(ClinicalTrials.gov)

March 2016

17/3/2016

Use of Dalfampridine in Primary Lateral Sclerosis

A Multicenter, 18-week Open Label Safety and Efficacy Trial of Dalfampridine in Primary Lateral Sclerosis

Motor Neuron Disease, Upper

Drug: dalfampridine

Weill Medical College of Cornell University

Hospital for Special Surgery, New York

Recruiting

18 Years

99 Years

All

Phase 1

United States